We Have a New Treatment, But You Can't Afford It

Author:
Christopher E. Desch
Search for other papers by Christopher E. Desch in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Christopher E. Desch, MD, is the National Medical Director of the NCCN and Co-Editor-in-Chief of JNCCN. As National Medical Director, Dr. Desch serves as the clinical leader for the broad spectrum of NCCN programs, including the NCCN Clinical Practice Guidelines in Oncology™. Dr. Desch previously served as hematologist/oncologist and Research Director for Virginia Cancer Institute. He is Chair of the Health Services Committee at the American Society of Clinical Oncology and has been a member of the American College of Physicians, the American Society of Hematology, and the Virginia Society of Hematology/Oncology.

  • Collapse
  • Expand
  • 1.

    Motzer RJ, Michaelson MD, Redman BG et al.. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:1624.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Pfizer Oncology. Sutent (sunitinib malate) capsules US fact sheet. Available at: http://www.pfizer.com/pfizer/download/news/asco/sutent_fact_sheet.pdf. Accessed June 26, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    American Cancer Society. Medicare Part D: what you need to know about the new drug benefit. Available at: http://www.cancer.org/docroot/MIT/MIT_3_1_Medicare_Part_D.asp. Accessed June 26, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    McGivney W. Coverage policy and use beyond the FDA-approved label. J Natl Compr Canc Netw 2006;4:99101.

  • 5.

    Sutent. Resources for health care professionals. Available at: http://www.sutent.com/content/Sutent_P1_Resources_HCP.jsp. Accessed June 26, 2006.

  • 6.

    Szabo L. Price of cancer drugs called ``mind-boggling'' [USA Today Web site]. July 22, 2004. Available at:http://www.keepmedia.com/pubs/USATODAY/2004/07/22/512271?extID=10037&oliID=229. Accessed June 29, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360:711715.

  • 8.

    Hillner BE, Smith TJ, Desch CE. Principles of cost effectiveness analysis for the assessment of current and new therapies. J Hematother 1993;2:501506.

  • 9.

    Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (traztuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909914.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Mayor S. NICE approves traztuzumab for early stage breast cancer. BMJ 2006;332:14091413.

  • 11.

    Alexander G, Casalino L, Meltzer D. Patient-physician communication about out-of-pocket costs. JAMA 2003;290:25432544.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 252 192 11
PDF Downloads 72 26 6
EPUB Downloads 0 0 0